{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:53:29Z","timestamp":1773100409615,"version":"3.50.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03743-8","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:44:55Z","timestamp":1756122295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recognizing potential immune checkpoint inhibitor-associated optic neuritis: insights from the FDA adverse event reporting system"],"prefix":"10.1007","volume":"45","author":[{"given":"Chang-Zhu","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"1","key":"3743_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-025-01735-5","volume":"17","author":"M Irizarry","year":"2025","unstructured":"Irizarry M, Surick I, Michael A, Kramer D (2025) Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database. Alzheimer\u2019s Res Ther 17(1):92","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"1","key":"3743_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-025-01699-6","volume":"17","author":"M Donati","year":"2025","unstructured":"Donati M, Boccia A, De Ponti F, Poluzzi E, Raschi E (2025) Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. Alzheimers Res Ther 17(1):80","journal-title":"Alzheimers Res Ther"},{"key":"3743_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/EB.S277760","volume":"12","author":"CW Yu","year":"2020","unstructured":"Yu CW, Yau M, Mezey N, Joarder I, Micieli JA (2020) Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review. Eye Brain 12:139\u2013167","journal-title":"Eye Brain"},{"issue":"11","key":"3743_CR4","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","volume":"127","author":"JH Francis","year":"2020","unstructured":"Francis JH, Jaben K, Santomasso BD, Canestraro J, Abramson DH, Chapman PB et al (2020) Immune checkpoint inhibitor-associated optic neuritis. Ophthalmology 127(11):1585\u20131589","journal-title":"Ophthalmology"},{"issue":"9","key":"3743_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","volume":"105","author":"BH Fortes","year":"2021","unstructured":"Fortes BH, Liou H, Dalvin LA (2021) Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Br J Ophthalmol 105(9):1263\u20131271","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"3743_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72(6):905\u2013908","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03743-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03743-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:03:33Z","timestamp":1766167413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03743-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03743-8","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chang-Zhu He, Qin Qiu and Yu He have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data for this study was sourced from the public FAERS database, which does not involve ethical considerations. Previous studies utilizing this database did not require ethical approval, and as such, this study is exempt from requiring approval from the Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"353"}}